Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000197430 | SCV000250170 | uncertain significance | not provided | 2024-07-28 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Although located in a calcium-binding EGF-like domain of the FBN2 gene, it does not substitute or introduce a cysteine residue (PMID: 19006240, 18767143); This variant is associated with the following publications: (PMID: 19006240, 18767143) |
Labcorp Genetics |
RCV000206321 | SCV000262021 | benign | Congenital contractural arachnodactyly | 2025-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002310785 | SCV000319331 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2023-08-15 | criteria provided, single submitter | clinical testing | The p.R827Q variant (also known as c.2480G>A), located in coding exon 19 of the FBN2 gene, results from a G to A substitution at nucleotide position 2480. The arginine at codon 827 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV005237691 | SCV005883248 | likely benign | not specified | 2024-12-27 | criteria provided, single submitter | clinical testing |